Treatment of Crohn's disease with certolizumab pegol

Expert Review of Clinical Immunology

Volumn 3, Issue 5, 2007, Pages 683-694

  Winter, Trevor A ^a,b   Sandborn, William J ^c   de Villiers, Willem J S ^d   Schreiber, Stefan ^e  

^a UNIVERSITY OF KENTUCKY   (United States)

^b GENENTECH INC   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BINDING PROTEIN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CIPROFLOXACIN; CORTICOSTEROID; ETANERCEPT; HYDROCORTISONE; INFLIXIMAB; MACROGOL; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; MONOCLONAL ANTIBODY; ONERCEPT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABDOMINAL ABSCESS; ABDOMINAL PAIN; ACNE; AREA UNDER THE CURVE; ARTICLE; BASAL CELL CARCINOMA; BINDING AFFINITY; CATARACT; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CROHN DISEASE; DEMYELINATING DISEASE; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG RESEARCH; DRUG TARGETING; EDEMA; GENETIC ENGINEERING; GLUCOSE INTOLERANCE; HEADACHE; HEART FAILURE; HIRSUTISM; HISTOPLASMOSIS; HUMAN; INFECTION; INJECTION SITE REACTION; INTESTINE CARCINOMA; INTESTINE FISTULA; INTESTINE OBSTRUCTION; INTESTINE SURGERY; LISTERIOSIS; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOPOROSIS; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PSYCHOSIS; QUALITY OF LIFE; RECTUM CANCER; RECURRENT DISEASE; REMISSION; RHINOPHARYNGITIS; SARCOIDOSIS; SIDE EFFECT; STAPHYLOCOCCUS INFECTION; STRIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TRACHEA OBSTRUCTION; TREATMENT OUTCOME; TUBERCULOSIS; WOUND HEALING;

EID: 34648817214     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.5.683     Document Type: Article

References (76)

1. Loftus EV, Jr., Schoenfeld P, Sandborn WJ. The epidemiology and natural history of Crohn's disease in population-based patient cohorts from North America: a systematic review. Aliment. Pharmacol. Ther. 16, 51-60 (2002).
2. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130, 940-987 (2006).
3. Modigliani R, Mary JY, Simon JF et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98, 811-818 (1990).
4. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 41, 209-214 (1997).
5. Thomsen OO, Cortot A, Jewell D et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group. N. Engl. J. Med. 339, 370-374 (1998).
6. Hanauer SB. Inflammatory bowel disease. N. Engl. J. Med. 334, 841-848 (1996).
7. Wild GE. The role of antibiotics in the management of Crohn's disease. Inflamm. Bowel Dis. 10, 321-323 (2004).
8. Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm. Bowel Dis. 10, 318-320 (2004).
9. Podolsky DK. Inflammatory bowel disease. N. Engl. J. Med. 347, 417-429 (2002).
10. Feagan BG, Rochon J, Fedorak RN et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N. Engl. J. Med. 332, 292-297 (1995).
11. Feagan BG, Fedorak RN, Irvine EJ et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342, 1627-1632 (2000).
12. Bouhnik Y, Lemann M, Mary JY et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 347, 215-219 (1996).
13. Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn'ss disease without concomitant steroids. Inflamm. Bowel Dis. 10, 79-84 (2004).
14. Soon SY, Ansari A, Yaneza M, Raoof S, Hirst J, Sanderson JD. Experience with the use of low-dose methotrexate for inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 16, 921-926 (2004).
15. Rutgeerts P. Review article: treatment of perianal fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 20(Suppl. 4), 106-110 (2004).
16. Hanauer SB, Korelitz BI, Rutgeerts P et al. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127, 723-729 (2004).
17. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of cordcosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121, 255-260 (2001).
18. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35, 360-362 (1994).
19. + lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157, 1261-1270 (1996).
20. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology 115, 182-205 (1998).
21. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119, 1148-1157 (2000).
22. MacDonald TT, Hutchings P, Choy MY, Murch S, Cooke A. Tumour necrosis factor-α and interferon-γ production measured at the single cell level in normal and inflamed human intestine. Clin. Exp. Immunol. 81, 301-305 (1990).
23. Reinecker HC, Steffen M, Witthoeft T et al. Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1 β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin. Exp. Immunol. 94, 174-181 (1993).
24. Schreiber S, Nikolaus S, Hampe J et al. Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease. Lancet 353, 459-461 (1999).
25. Targan SR, Hanauer SB, van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. Crohn's Disease cA2 Study Group. N. Engl. J. Med. 337, 1029-1035 (1997).
26. Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N. Engl. J. Med. 340, 1398-1405 (1999).
27. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359, 1541-1549 (2002).
28. Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 126, 402-413 (2004).
29. Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for flstulizing Crohn's disease. N. Engl. J. Med. 350, 876-885 (2004).
30. Baert F, Noman M, Vermeire S et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348, 601-608 (2003).
31. Rutgeerts P, Van Assche G, Vermeire S. Review article: infliximab therapy for inflammatory bowel disease - seven years on. Aliment. Pharmacol. Ther. 23, 451-463 (2006).
32. Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 124, 917-924 (2003).
33. Sandborn WJ, Faubion WA. Biologics in inflammatory bowel disease: how much progress have we made? Gut 53, 1366-1373 (2004).
34. Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22, 30-43 (2006).
35. Mackey AC, Green L, Liang LC, Dinndorf P, Avigan M. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44, 265-267 (2007).
36. Navarro JT, Ribera JM, Mate JL et al. Hepatosplenic T-γdelta lymphoma in a patient with Crohn's disease treated with azathioprine. Leuk. Lymphoma 44, 531-533 (2003).
37. Mittal S, Milner BJ, Johnston PW, Culligan DJ. A case of hepatosplenic γ-δ T-cell lymphoma with a transient response to fludarabine and alemtuzumab. Eur. J. Haematol. 76, 531-534 (2006).
38. Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121, 1088-1094 (2001).
39. Rutgeerts P, Sandborn WJ, Fedorak RN et al. Onercept for moderate-to-severe Crohn's disease, a randomized, double-blind, placebo-controlled trial. Clin. Gastroenterol. Hepatol. 4(7), 888-893 (2006).
40. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121, 1145-1157 (2001).
41. Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJ. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 50, 206-211 (2002).
42. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
43. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-α in Crohn's disease. Lancet 349, 521-524 (1997).
44. Sandborn WJ, Feagan BG, Radford-Smith G et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor α, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 53, 1485-1493 (2004).
45. Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patd J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 23, 617-628 (2006).
46. Papadakis KA. Adalimumab for the treatment of Crohn's disease. Expert Rev. Clin. Immunol. 2, 11-15 (2006).
47. Shen C, Assche GV, Colpaert S et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21, 251-258 (2005).
48. Van de Putte LB, Atkins C, Malaise M et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. 63, 508-516 (2004).
49. Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 99, 1984-1989 (2004).
50. Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monodonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 130, 323-333 (2006).
51. Sandbom WJ, Hanauer SB, Rutgeerts PJ et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) (Epub ahead of print).
52. Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132, 52-65 (2007).
53. Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med. 146, 829-838 (2007).
54. Rose-John S, Schooltink H. CDP-870. Celltech/Pfizer. Curr. Opin. Investig. Drugs 4, 588-592 (2003).
55. Choy EH, Hazleman B, Smith M et al. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a Phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxf.) 41, 1133-1137 (2002).
56. Fossati G, Nesbit AM. Effect of the anti-TNF agents, adalimumab, etanercept, infliximab, and certolizumab pegol (CDP870) on the induction of apoptosis in activated peripheral blood lymphocytes and monocytes. Am. J. Gastroenterol. 100, S298 (2005) (Abstract 806).
57. Fossati G, Nesbit AM. In vitro complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by the anti-TNF agents adalimumab, etanercept, infliximab and certolizumab pegol (CDP870). Am. J. Gastroenterol. 100, S299 (2005) (Abstract 807).
58. Winter TA, Wright J, Ghosh S, Jahnsen J, Innes A, Round P. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study. Aliment. Pharmacol. Ther. 20, 1337-1346 (2004).
59. Schreiber S, Rutgeerts P, Fedorak RN et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807-818 (2005).
60. Winter TA, de Villiers WJ, Mardini HE. CDP870 in Crohn's disease: reconsidering endpoints. Inflamm. Bowel Dis. 12, 249 (2006).
61. Schreiber S, Khaliz-Kareemi M, Lawrence IC et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N. Engl. J. Med. 357, 23-34 (2007).
62. Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab for the treatment of Crohn's disease. N. Engl. J. Med. 357, 12-22 (2007).
63. Schreiber S, Hanauer SB, Feagan BG, Bloomfield R, Rutgeerts P, Sandborn WJ. Long-term treatment with certolizumab pegol for 18 months in patients with active Crohn's disease: PRECiSE 3 efficacy results. Gastroenterology 132(Suppl. 2), 504 (2007) (Abstract T1271).
64. Sandborn WJ, Hanauer SB, Rutgeerts PJ, Colombel JF. Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology 132(Suppl. 2), 505 (2007) (Abstract T 1274).
65. Schreiber S, Sandborn WJ, Lawrence I, Hanauer SB, McColm JA, Bloomfield R. Certolizumab Pegol, a humanized anti-TNF pegylated Fab' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease. A Phase III study (PRECiSE). Presented at: The 13th United European Gastroenterology Week. Copenhagen, Denmark, October 15-19, 2005.
66. Schreiber S, Feagan B, Hanauer SB, Rutgeerts P, McColm JA, Sandborn WJ. Safety and tolerability of subcutaneous (sc) certolizumab pegol in active Crohn's disease (CD): results from t-wo Phase III studies (PRECiSE program) Gastroenterology 130(Suppl. 2), 479 (2006) (Abstract T1126).
67. Colombel J, Schreiber S, Hanauer S, Rutgeerts P, Sandborn W. Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: results from PRECiSE 3 and 4. Gastroenterology 132(Suppl. 2), 503 (2007) (Abstract T1267).
68. Ito H, Takazoe M, Fukuda Y et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126, 989-996 (2004).
69. Atreya R, Mudter J, Finotto S et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6, 583-588 (2000).
70. Gordon FH, Lai CW, Hamilton MI et al. A randomized placebo-controlled trial of a humanized monoclonal antibody to α4 integrin in active Crohn's disease. Gastroenterology 121, 268-274 (2001).
71. Ghosh S, Goldin E, Gordon FH et al. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348, 24-32 (2003).
72. Sandborn WJ, Colombel JF, Enns R et al. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925 (2005).
73. Feagan BG, Greenberg GR, Wild G. Efficacy and safety of a4β7 antibody in active Crohn's disease. Gastroenterology 124, A25-A26 (2003).
74. Korzenik JR, Dieckgraefe BK, Valentine JF, Hausman DF, Gilbert MJ. Sargramostim for active Crohn's disease. N. Engl. J. Med. 352, 2193-2201 (2005).
75. Mannon PJ, Fuss IJ, Mayer L et al. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079 (2004).
76. Hommes DW, Mikhajlova TL, Stoinov S et al. Fontolizumab, a humanised anti-interferon γ antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut 55, 1131-1137 (2006).